Bainco International Investors Has Increased Adamas Pharmaceuticals Com (ADMS) Position By $1.24 Million; Neuralstem (CUR) Shorts Raised By 2.45%

June 14, 2018 - By Shannon Black

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Bainco International Investors increased Adamas Pharmaceuticals Inc Com (ADMS) stake by 268.66% reported in 2018Q1 SEC filing. Bainco International Investors acquired 54,000 shares as Adamas Pharmaceuticals Inc Com (ADMS)’s stock rose 13.10%. The Bainco International Investors holds 74,100 shares with $1.77M value, up from 20,100 last quarter. Adamas Pharmaceuticals Inc Com now has $740.39 million valuation. The stock decreased 0.87% or $0.24 during the last trading session, reaching $27.44. About 346,640 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since June 14, 2017 and is uptrending. It has outperformed by 76.18% the S&P500. Some Historical ADMS News: ; 19/04/2018 – ADAMAS PHARMACEUTICALS INC – SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES; 29/03/2018 – ADAMAS FIN ASIA LTD – UPDATE ON DISPOSAL OF INTEREST IN GLOBAL PHARM; 15/05/2018 – Sectoral Asset Management Buys 1.3% Position in Adamas Pharma; 07/05/2018 – Adamas Pharma at Deutsche Bank Health Care Conference Tomorrow; 14/05/2018 – Janus Henderson Group Buys New 3.4% Position in Adamas Pharma; 10/04/2018 – Adamas Pharma at Deutsche Bank Health Care Conference May 8; 26/03/2018 – Adamas Pharma Presenting at Conference Tomorrow; 19/04/2018 – ADAMAS PHARMACEUTICALS INC – RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED; 14/05/2018 – Broadfin Adds Adamas Pharma, Exits Endo, Cuts AngioDynamics: 13F; 03/04/2018 – Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment

Neuralstem Inc (NASDAQ:CUR) had an increase of 2.45% in short interest. CUR’s SI was 781,600 shares in June as released by FINRA. Its up 2.45% from 762,900 shares previously. With 90,500 avg volume, 9 days are for Neuralstem Inc (NASDAQ:CUR)’s short sellers to cover CUR’s short positions. The stock decreased 1.75% or $0.03 during the last trading session, reaching $1.68. About 32,006 shares traded. Neuralstem, Inc. (NASDAQ:CUR) has declined 61.82% since June 14, 2017 and is downtrending. It has underperformed by 74.39% the S&P500. Some Historical CUR News: ; 02/04/2018 – Neuralstem 2017 Loss/Shr $1.20; 02/04/2018 – Neuralstem Reports Year End 2017 Fiscal Results and Business Update; 11/04/2018 – Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day; 02/04/2018 – NEURALSTEM INC – AT DECEMBER 31, 2017, CASH AND INVESTMENTS WAS $11.7 MLN AS COMPARED TO $20.2 MLN AT DECEMBER 31, 2016; 13/03/2018 – Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cor; 12/03/2018 Neuralstem to Participate at Upcoming Investor Conferences; 15/05/2018 – Neuralstem 1Q Loss/Shr 14c; 21/04/2018 – DJ Neuralstem Inc, Inst Holders, 1Q 2018 (CUR); 10/04/2018 – Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord; 03/05/2018 – Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company has market cap of $25.47 million. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It currently has negative earnings. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome.

More recent Neuralstem, Inc. (NASDAQ:CUR) news were published by: Globenewswire.com which released: “Neuralstem to Participate at the BIO 2018 International Convention” on May 29, 2018. Also Nasdaq.com published the news titled: “Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors” on June 12, 2018. Globenewswire.com‘s news article titled: “Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete …” with publication date: June 04, 2018 was also an interesting one.

More recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Globenewswire.com which released: “Adamas Announces New Employment Inducement Grant” on June 08, 2018. Also Seekingalpha.com published the news titled: “Adamas Pharmaceuticals: Interesting Over The Long Term” on May 18, 2018. Nasdaq.com‘s news article titled: “Adamas Announces Publication of Pharmacokinetic Data for GOCOVRIâ„¢ in Clinical Pharmacokinetics” with publication date: May 24, 2018 was also an interesting one.

Among 13 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Adamas Pharmaceuticals had 36 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, April 28 by Mizuho. As per Thursday, May 12, the company rating was maintained by Mizuho. Noble Financial maintained the stock with “Buy” rating in Wednesday, August 9 report. The firm has “Market Outperform” rating by JMP Securities given on Friday, April 1. The rating was maintained by Piper Jaffray on Thursday, August 31 with “Buy”. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Friday, November 3. Mizuho has “Buy” rating and $48.0 target. The rating was maintained by Cowen & Co with “Buy” on Wednesday, August 9. As per Friday, September 15, the company rating was maintained by Needham. The stock has “Buy” rating by Mizuho on Tuesday, August 15. Noble Financial initiated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Friday, June 17. Noble Financial has “Buy” rating and $25 target.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart